Table 7. Rates of confirmed myocarditis following Pfizer-BioNTech and Moderna COVID-19 vaccines in the Republic of Korea, by age and sex (as of 31 January 2022).

Age group (years)	Pfizer-BioNTech (number of events per 1 million doses)				Moderna (number of events per 1 million doses)
	1st dose		2nd dose		1st dose		2nd dose
	Male	Female	Male	Female	Male	Female	Male	Female
12–17	12.9	4.3	23.6	3.7	–	–	–	–
18–19	14.6	8.2	14.7	8.3	13.9	0.0	47.5	15.6
20–29	4.7	4.7	5.4	1.3	10.0	10.4	37.2	4.8
30–39	10.4	5.7	2.2	3.3	12.3	9.4	7.8	6.4
40–49	2.1	2.5	2.9	2.9	4.3	7.6	3.3	3.9
50–59	1.2	4.0	1.9	2.3	1.9	8.6	1.9	0.0
≥ 60	0.0	0.0	0.7	0.4	0.0	0.0	0.0	0.0
Total	4.8	3.5	5.0	2.4	6.4	8.4	11.5	3.5

Source: Data are reproduced with permission from the Korea Disease Control and Prevention Agency, WHO Global Advisory Committee on Vaccine Safety meeting, unpublished presentation, January 2022.